← back to search

Michael P. Whyte

Missouri Bone and Joint Center · US
Area of research
Oncology · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Bone health and treatments, Alkaline Phosphatase Research Studies, Parathyroid Disorders and Treatments, and Bone health and osteoporosis research.
h-index
87
citations
29,240
works
671
NIH funding
primary concept
email

Recent publications

Hypophosphatasia: who among us is a carrier?
2026cited by 0position: contributordoi
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period
JBMR Plus 2024cited by 20position: middledoi
Pediatric hypophosphatasia: avoid diagnosis missteps!
2024cited by 5position: contributordoi
LRP6 High Bone Mass Characterized in Two Generations Harboring a Unique Mutation of Low-Density Lipoprotein Receptor-Related Protein 6.
2023cited by 6position: contributordoi
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
The Journal of Clinical Endocrinology & Metabolism 2022cited by 75position: middledoi
Dysosteosclerosis: Clinical and Radiological Evolution Reflecting Genetic Heterogeneity.
2022cited by 6position: contributordoi
Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia
The Journal of Clinical Endocrinology & Metabolism 2021cited by 88position: middledoi
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
Calcified Tissue International 2021cited by 47position: middledoi
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.
2021cited by 36position: contributordoi
Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody.
2021cited by 4position: contributordoi
X-Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3'-UTR Mutation c.*231A>G (A Retrospective Case-Control Study).
2020cited by 12position: contributordoi
ZNF687 Mutations in an Extended Cohort of Neoplastic Transformations in Paget's Disease of Bone: Implications for Clinical Pathology.
2020cited by 9position: contributordoi
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
The Lancet 2019cited by 364position: middledoi
Natural History of Perinatal and Infantile Hypophosphatasia: A Retrospective Study
The Journal of Pediatrics 2019cited by 68position: firstdoi
Skeletal Fluorosis Due To Inhalation Abuse of a Difluoroethane-Containing Computer Cleaner
Journal of Bone and Mineral Research 2016cited by 30position: lastdoi
Factors influencing success of clinical genome sequencing across a broad spectrum of disorders
Nature Genetics 2015cited by 386position: middledoi
Periodontal Defects in the A116T Knock-in Murine Model of Odontohypophosphatasia
Journal of Dental Research 2015cited by 49position: middledoi
Whole-exome sequencing identifies mutations in the nucleoside transporter gene SLC29A3 in dysosteosclerosis, a form of osteopetrosis
Human Molecular Genetics 2012cited by 90position: middledoi
Enzyme replacement prevents enamel defects in hypophosphatasia mice
Journal of Bone and Mineral Research 2012cited by 89position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 8 papers (2020–2026)Wolfgang Högler · University of Birmingham6 papers (2012–2024)Raja Padidela · University of Manchester5 papers (2019–2024) · 5 papers (2019–2024)Erik A. Imel · Indiana University School of Medicine5 papers (2019–2024)Anthony A. Portale · University of California, San Francisco5 papers (2019–2024)Craig F. Munns · Children's Medical Research Institute4 papers (2019–2024)Ola Nilsson · Karolinska University Hospital4 papers (2019–2024)Leanne M. Ward · University of Birmingham4 papers (2019–2024)Angel Chen · University of California, Santa Barbara4 papers (2021–2024)Jill H. Simmons · Children's Healthcare of Atlanta4 papers (2019–2024)Francis H. Glorieux · Indiana University – Purdue University Indianapolis4 papers (2019–2024) · 4 papers (2019–2024) · 4 papers (2019–2024)Alison Skrinar · Indiana University – Purdue University Indianapolis4 papers (2019–2022) · 3 papers (2019–2024)Pisit Pitukcheewanont · Lumos Pharma (United States)3 papers (2019–2024)Andrew Biggin · University of Liverpool3 papers (2019–2024)Farzana Perwad · University of California, San Francisco3 papers (2019–2024)Etienne Sochett · Hospital for Sick Children3 papers (2019–2024)